S&P 500   3,920.63 (+1.01%)
DOW   31,930.97 (+1.25%)
QQQ   321.77 (+0.09%)
AAPL   124.26 (-1.27%)
MSFT   232.83 (-0.19%)
FB   264.53 (-0.50%)
GOOGL   2,070.04 (+0.48%)
AMZN   3,151.69 (-1.34%)
TSLA   728.23 (+4.21%)
NVDA   569.60 (+0.69%)
BABA   249.83 (-1.16%)
CGC   35.59 (+0.79%)
GE   13.16 (+4.53%)
MU   90.77 (+2.88%)
NIO   51.09 (+4.03%)
AMD   85.79 (+1.24%)
T   29.36 (+0.62%)
F   12.00 (+3.27%)
ACB   11.39 (+1.61%)
DIS   199.05 (+0.99%)
BA   226.84 (+6.94%)
NFLX   550.54 (+0.80%)
BAC   36.21 (+1.94%)
S&P 500   3,920.63 (+1.01%)
DOW   31,930.97 (+1.25%)
QQQ   321.77 (+0.09%)
AAPL   124.26 (-1.27%)
MSFT   232.83 (-0.19%)
FB   264.53 (-0.50%)
GOOGL   2,070.04 (+0.48%)
AMZN   3,151.69 (-1.34%)
TSLA   728.23 (+4.21%)
NVDA   569.60 (+0.69%)
BABA   249.83 (-1.16%)
CGC   35.59 (+0.79%)
GE   13.16 (+4.53%)
MU   90.77 (+2.88%)
NIO   51.09 (+4.03%)
AMD   85.79 (+1.24%)
T   29.36 (+0.62%)
F   12.00 (+3.27%)
ACB   11.39 (+1.61%)
DIS   199.05 (+0.99%)
BA   226.84 (+6.94%)
NFLX   550.54 (+0.80%)
BAC   36.21 (+1.94%)
S&P 500   3,920.63 (+1.01%)
DOW   31,930.97 (+1.25%)
QQQ   321.77 (+0.09%)
AAPL   124.26 (-1.27%)
MSFT   232.83 (-0.19%)
FB   264.53 (-0.50%)
GOOGL   2,070.04 (+0.48%)
AMZN   3,151.69 (-1.34%)
TSLA   728.23 (+4.21%)
NVDA   569.60 (+0.69%)
BABA   249.83 (-1.16%)
CGC   35.59 (+0.79%)
GE   13.16 (+4.53%)
MU   90.77 (+2.88%)
NIO   51.09 (+4.03%)
AMD   85.79 (+1.24%)
T   29.36 (+0.62%)
F   12.00 (+3.27%)
ACB   11.39 (+1.61%)
DIS   199.05 (+0.99%)
BA   226.84 (+6.94%)
NFLX   550.54 (+0.80%)
BAC   36.21 (+1.94%)
S&P 500   3,920.63 (+1.01%)
DOW   31,930.97 (+1.25%)
QQQ   321.77 (+0.09%)
AAPL   124.26 (-1.27%)
MSFT   232.83 (-0.19%)
FB   264.53 (-0.50%)
GOOGL   2,070.04 (+0.48%)
AMZN   3,151.69 (-1.34%)
TSLA   728.23 (+4.21%)
NVDA   569.60 (+0.69%)
BABA   249.83 (-1.16%)
CGC   35.59 (+0.79%)
GE   13.16 (+4.53%)
MU   90.77 (+2.88%)
NIO   51.09 (+4.03%)
AMD   85.79 (+1.24%)
T   29.36 (+0.62%)
F   12.00 (+3.27%)
ACB   11.39 (+1.61%)
DIS   199.05 (+0.99%)
BA   226.84 (+6.94%)
NFLX   550.54 (+0.80%)
BAC   36.21 (+1.94%)
Log in
NASDAQ:HZNP

Horizon Therapeutics Public Competitors

$93.54
+9.26 (+10.99 %)
(As of 02/24/2021 01:16 PM ET)
Add
Compare
Today's Range
$85.50
Now: $93.54
$94.45
50-Day Range
$71.83
MA: $81.50
$91.15
52-Week Range
$23.81
Now: $93.54
$91.76
Volume98,567 shs
Average Volume1.97 million shs
Market Capitalization$20.65 billion
P/E Ratio25.56
Dividend YieldN/A
Beta1.15

Competitors

Horizon Therapeutics Public (NASDAQ:HZNP) Vs. JNJ, LLY, MRK, PFE, ABBV, and BMY

Should you be buying HZNP stock or one of its competitors? Companies in the sub-industry of "pharmaceuticals" are considered alternatives and competitors to Horizon Therapeutics Public, including Johnson & Johnson (JNJ), Eli Lilly and (LLY), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), and Bristol-Myers Squibb (BMY).

Horizon Therapeutics Public (NASDAQ:HZNP) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Horizon Therapeutics Public and Johnson & Johnson's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Horizon Therapeutics Public43.55%25.66%14.19%
Johnson & Johnson21.01%34.64%13.40%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Horizon Therapeutics Public and Johnson & Johnson, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Horizon Therapeutics Public00803.00
Johnson & Johnson031202.80

Horizon Therapeutics Public currently has a consensus price target of $101.8889, indicating a potential upside of 8.21%. Johnson & Johnson has a consensus price target of $178.9333, indicating a potential upside of 9.87%. Given Johnson & Johnson's higher probable upside, analysts clearly believe Johnson & Johnson is more favorable than Horizon Therapeutics Public.

Earnings and Valuation

This table compares Horizon Therapeutics Public and Johnson & Johnson's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Horizon Therapeutics Public$1.30 billion15.95$573.02 million$1.9448.44
Johnson & Johnson$82.06 billion5.23$15.12 billion$8.6818.77

Johnson & Johnson has higher revenue and earnings than Horizon Therapeutics Public. Johnson & Johnson is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

88.6% of Horizon Therapeutics Public shares are held by institutional investors. Comparatively, 67.3% of Johnson & Johnson shares are held by institutional investors. 4.3% of Horizon Therapeutics Public shares are held by insiders. Comparatively, 0.3% of Johnson & Johnson shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Horizon Therapeutics Public has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500.

Summary

Horizon Therapeutics Public beats Johnson & Johnson on 8 of the 14 factors compared between the two stocks.

Horizon Therapeutics Public (NASDAQ:HZNP) and Eli Lilly and (NYSE:LLY) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Horizon Therapeutics Public and Eli Lilly and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Horizon Therapeutics Public43.55%25.66%14.19%
Eli Lilly and24.01%166.45%15.18%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Horizon Therapeutics Public and Eli Lilly and, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Horizon Therapeutics Public00803.00
Eli Lilly and041012.80

Horizon Therapeutics Public currently has a consensus price target of $101.8889, indicating a potential upside of 8.21%. Eli Lilly and has a consensus price target of $192.60, indicating a potential downside of 6.12%. Given Horizon Therapeutics Public's stronger consensus rating and higher probable upside, equities research analysts clearly believe Horizon Therapeutics Public is more favorable than Eli Lilly and.

Earnings and Valuation

This table compares Horizon Therapeutics Public and Eli Lilly and's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Horizon Therapeutics Public$1.30 billion15.95$573.02 million$1.9448.44
Eli Lilly and$22.32 billion8.81$8.32 billion$6.0433.98

Eli Lilly and has higher revenue and earnings than Horizon Therapeutics Public. Eli Lilly and is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

88.6% of Horizon Therapeutics Public shares are held by institutional investors. Comparatively, 75.6% of Eli Lilly and shares are held by institutional investors. 4.3% of Horizon Therapeutics Public shares are held by insiders. Comparatively, 0.1% of Eli Lilly and shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Horizon Therapeutics Public has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, Eli Lilly and has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500.

Summary

Eli Lilly and beats Horizon Therapeutics Public on 8 of the 15 factors compared between the two stocks.

Horizon Therapeutics Public (NASDAQ:HZNP) and Merck & Co., Inc. (NYSE:MRK) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Horizon Therapeutics Public and Merck & Co., Inc.'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Horizon Therapeutics Public43.55%25.66%14.19%
Merck & Co., Inc.24.33%53.83%16.83%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Horizon Therapeutics Public and Merck & Co., Inc., as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Horizon Therapeutics Public00803.00
Merck & Co., Inc.021302.87

Horizon Therapeutics Public currently has a consensus price target of $101.8889, indicating a potential upside of 8.21%. Merck & Co., Inc. has a consensus price target of $95.3571, indicating a potential upside of 27.26%. Given Merck & Co., Inc.'s higher probable upside, analysts clearly believe Merck & Co., Inc. is more favorable than Horizon Therapeutics Public.

Earnings and Valuation

This table compares Horizon Therapeutics Public and Merck & Co., Inc.'s revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Horizon Therapeutics Public$1.30 billion15.95$573.02 million$1.9448.44
Merck & Co., Inc.$46.84 billion4.05$9.84 billion$5.1914.45

Merck & Co., Inc. has higher revenue and earnings than Horizon Therapeutics Public. Merck & Co., Inc. is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

88.6% of Horizon Therapeutics Public shares are held by institutional investors. Comparatively, 72.9% of Merck & Co., Inc. shares are held by institutional investors. 4.3% of Horizon Therapeutics Public shares are held by insiders. Comparatively, 0.3% of Merck & Co., Inc. shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Horizon Therapeutics Public has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500.

Horizon Therapeutics Public (NASDAQ:HZNP) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Horizon Therapeutics Public and Pfizer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Horizon Therapeutics Public43.55%25.66%14.19%
Pfizer17.85%24.88%9.32%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Horizon Therapeutics Public and Pfizer, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Horizon Therapeutics Public00803.00
Pfizer010502.33

Horizon Therapeutics Public currently has a consensus price target of $101.8889, indicating a potential upside of 8.21%. Pfizer has a consensus price target of $39.5333, indicating a potential upside of 16.86%. Given Pfizer's higher probable upside, analysts clearly believe Pfizer is more favorable than Horizon Therapeutics Public.

Earnings and Valuation

This table compares Horizon Therapeutics Public and Pfizer's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Horizon Therapeutics Public$1.30 billion15.95$573.02 million$1.9448.44
Pfizer$51.75 billion3.63$16.27 billion$2.9511.46

Pfizer has higher revenue and earnings than Horizon Therapeutics Public. Pfizer is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

88.6% of Horizon Therapeutics Public shares are held by institutional investors. Comparatively, 67.4% of Pfizer shares are held by institutional investors. 4.3% of Horizon Therapeutics Public shares are held by insiders. Comparatively, 0.1% of Pfizer shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Horizon Therapeutics Public has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500.

Summary

Horizon Therapeutics Public beats Pfizer on 10 of the 14 factors compared between the two stocks.

Horizon Therapeutics Public (NASDAQ:HZNP) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Horizon Therapeutics Public and AbbVie's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Horizon Therapeutics Public43.55%25.66%14.19%
AbbVie18.16%439.24%13.22%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Horizon Therapeutics Public and AbbVie, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Horizon Therapeutics Public00803.00
AbbVie141402.68

Horizon Therapeutics Public currently has a consensus price target of $101.8889, indicating a potential upside of 8.21%. AbbVie has a consensus price target of $114.4118, indicating a potential upside of 5.32%. Given Horizon Therapeutics Public's stronger consensus rating and higher probable upside, equities research analysts clearly believe Horizon Therapeutics Public is more favorable than AbbVie.

Earnings and Valuation

This table compares Horizon Therapeutics Public and AbbVie's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Horizon Therapeutics Public$1.30 billion15.95$573.02 million$1.9448.44
AbbVie$33.27 billion5.77$7.88 billion$8.9412.17

AbbVie has higher revenue and earnings than Horizon Therapeutics Public. AbbVie is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

88.6% of Horizon Therapeutics Public shares are held by institutional investors. Comparatively, 67.5% of AbbVie shares are held by institutional investors. 4.3% of Horizon Therapeutics Public shares are held by insiders. Comparatively, 0.1% of AbbVie shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Horizon Therapeutics Public has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500.

Summary

Horizon Therapeutics Public beats AbbVie on 9 of the 14 factors compared between the two stocks.

Horizon Therapeutics Public (NASDAQ:HZNP) and Bristol-Myers Squibb (NYSE:BMY) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Horizon Therapeutics Public and Bristol-Myers Squibb's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Horizon Therapeutics Public43.55%25.66%14.19%
Bristol-Myers Squibb-0.11%27.48%10.77%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Horizon Therapeutics Public and Bristol-Myers Squibb, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Horizon Therapeutics Public00803.00
Bristol-Myers Squibb041012.80

Horizon Therapeutics Public currently has a consensus price target of $101.8889, indicating a potential upside of 8.21%. Bristol-Myers Squibb has a consensus price target of $74.2667, indicating a potential upside of 18.88%. Given Bristol-Myers Squibb's higher probable upside, analysts clearly believe Bristol-Myers Squibb is more favorable than Horizon Therapeutics Public.

Earnings and Valuation

This table compares Horizon Therapeutics Public and Bristol-Myers Squibb's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Horizon Therapeutics Public$1.30 billion15.95$573.02 million$1.9448.44
Bristol-Myers Squibb$26.15 billion5.37$3.44 billion$4.6913.37

Bristol-Myers Squibb has higher revenue and earnings than Horizon Therapeutics Public. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

88.6% of Horizon Therapeutics Public shares are held by institutional investors. Comparatively, 72.4% of Bristol-Myers Squibb shares are held by institutional investors. 4.3% of Horizon Therapeutics Public shares are held by insiders. Comparatively, 0.1% of Bristol-Myers Squibb shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Horizon Therapeutics Public has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, Bristol-Myers Squibb has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500.

Summary

Horizon Therapeutics Public beats Bristol-Myers Squibb on 8 of the 15 factors compared between the two stocks.


Horizon Therapeutics Public Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Johnson & Johnson logo
JNJ
Johnson & Johnson
2.6$162.93+1.5%$422.37 billion$82.06 billion25.62
Eli Lilly and logo
LLY
Eli Lilly and
2.1$205.24+1.3%$194.06 billion$22.32 billion33.54
Merck & Co., Inc. logo
MRK
Merck & Co., Inc.
2.4$74.97+0.6%$188.59 billion$46.84 billion16.59
Pfizer logo
PFE
Pfizer
2.6$33.81+0.3%$188.49 billion$51.75 billion21.81
AbbVie logo
ABBV
AbbVie
2.8$108.78+2.3%$187.62 billion$33.27 billion23.00Dividend Announcement
Bristol-Myers Squibb logo
BMY
Bristol-Myers Squibb
2.3$62.70+3.2%$136.04 billion$26.15 billion-569.95
Zoetis logo
ZTS
Zoetis
1.8$161.15+1.0%$75.80 billion$6.26 billion47.82Insider Buying
Royalty Pharma logo
RPRX
Royalty Pharma
1.6$48.01+2.3%$18.21 billionN/A0.00Earnings Announcement
Analyst Revision
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
1.9$175.08+10.1%$8.77 billion$2.16 billion55.23Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Down
Perrigo logo
PRGO
Perrigo
2.6$41.89+1.5%$5.80 billion$4.84 billion-698.05Upcoming Earnings
Dividend Increase
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.6$22.68+0.7%$4.04 billion$114.62 million-9.15Upcoming Earnings
Analyst Downgrade
Analyst Revision
Pacira BioSciences logo
PCRX
Pacira BioSciences
1.9$78.32+3.0%$3.30 billion$421.03 million27.58Upcoming Earnings
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.6$27.14+1.9%$3.09 billion$306.49 million30.49Earnings Announcement
Endo International logo
ENDP
Endo International
1.4$10.02+2.1%$2.26 billion$2.91 billion-14.74Upcoming Earnings
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.4$31.01+4.6%$1.56 billion$392.76 million12.87Upcoming Earnings
News Coverage
Omeros logo
OMER
Omeros
1.0$22.89+3.2%$1.37 billion$111.81 million-9.62Upcoming Earnings
Insider Selling
News Coverage
Zogenix logo
ZGNX
Zogenix
1.7$23.57+2.9%$1.27 billion$3.65 million-2.48Upcoming Earnings
BioDelivery Sciences International logo
BDSI
BioDelivery Sciences International
2.2$4.40+4.1%$427.19 million$111.39 million31.43
Paratek Pharmaceuticals logo
PRTK
Paratek Pharmaceuticals
1.5$7.73+2.6%$343.68 million$16.54 million-3.14
Lannett logo
LCI
Lannett
2.0$6.17+3.9%$245.51 million$545.74 million-8.57
Assembly Biosciences logo
ASMB
Assembly Biosciences
1.6$5.65+3.4%$180.30 million$15.96 million-3.42Upcoming Earnings
Gap Down
Cumberland Pharmaceuticals logo
CPIX
Cumberland Pharmaceuticals
0.7$3.47+2.6%$50.76 million$47.53 million-15.77Gap Down
This page was last updated on 2/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.